Inogen Inc (INGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inogen Inc (INGN) has a cash flow conversion efficiency ratio of -0.037x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.68 Million) by net assets ($182.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Inogen Inc balance sheet independence to measure how much of total assets are equity-financed.
Inogen Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Inogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Inogen Inc (INGN) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Inogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tele2 AB (publ)
ST:TEL2-A
|
0.118x |
|
United Pharm
KO:033270
|
0.077x |
|
Niu Technologies
F:0O9
|
N/A |
|
Melar Acquisition Corp. I Class A Ordinary Shares
NASDAQ:MACI
|
-0.001x |
|
Gencor Industries Inc
NYSE MKT:GENC
|
0.052x |
|
Bluerock Acquisition Corp. Class A Ordinary Shares
NASDAQ:BLRK
|
10.328x |
|
La Française de l'Energie S.A.
PA:FDE
|
0.040x |
|
Pappajack Bhd
KLSE:0242
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Inogen Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Inogen Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see INGN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $192.23 Million | $-11.22 Million | -0.058x | -271.53% |
| 2024-12-31 | $173.86 Million | $5.91 Million | 0.034x | +315.43% |
| 2023-12-31 | $204.81 Million | $-3.23 Million | -0.016x | +87.49% |
| 2022-12-31 | $297.41 Million | $-37.53 Million | -0.126x | -297.70% |
| 2021-12-31 | $370.23 Million | $23.63 Million | 0.064x | -39.70% |
| 2020-12-31 | $349.62 Million | $37.01 Million | 0.106x | -10.12% |
| 2019-12-31 | $344.62 Million | $40.59 Million | 0.118x | -39.04% |
| 2018-12-31 | $310.42 Million | $59.98 Million | 0.193x | -27.49% |
| 2017-12-31 | $227.04 Million | $60.49 Million | 0.266x | +56.33% |
| 2016-12-31 | $182.09 Million | $31.03 Million | 0.170x | -40.15% |
| 2015-12-31 | $134.02 Million | $38.16 Million | 0.285x | +114.33% |
| 2014-12-31 | $118.15 Million | $15.70 Million | 0.133x | -44.46% |
| 2013-12-31 | $56.30 Million | $13.47 Million | 0.239x | +70.71% |
| 2012-12-31 | $28.57 Million | $4.00 Million | 0.140x | -43.05% |
| 2011-12-31 | $7.56 Million | $1.86 Million | 0.246x | -- |
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen the… Read more